IPXL Impax Laboratories, Inc. (delisted)

www.rothmanresearch.com - The biggest nightmare for pharmaceuticals is when their drug patent expires. Patent expiration is daunting for any branded pharmaceutical as it leaves the door wide open for generic versions of the company's drug which have a direct impact on the revenue stream this drug brings to the patented drug manufacturer. Branded drug production normally involves huge investments in Research and Development (R&D) from companies like Eli Lilly & Co. (NYSE: LLY) and the success of the drugs is very often a gamble. However, a successful propriety drug which meets all of the FDA's criteria can be a virtual gold mine for the company. An example is Eli Lilly's best-selling drug Zyprexa, used in the treatment of Schizophrenia and other psychological disorders, which contributed to about 23% of the company's sales in 2009 and which will expire in 2011.

www.rothmanresearch.com is a source for investors seeking free information on the major drug manufacturers sector; investors are encouraged to sign up for free at http://www.rothmanresearch.com/index.php?id=6&name=Register.

"Eli Lilly is facing some mind-boggling strategic issues with at least 5 of its best-sellers lining for the shoot as they near patent expiration starting at the close of 2011 up to 2017. The company will be losing a massive portion of its revenue stream to patent expiration," commented Jack Benassi of www.rothmanresearch.com. "Eli Lilly has made some crucial maneuvers to cut cost like the trimming of 5,500 positions in 2009 and its acquisition of ImClone which increased its product pipeline with promising drugs like Erbitux for colon cancer treatment. M&A has been a growing trend in the pharma circle in a bid to cushion patent expiration impacts on revenue through addition of new products. Some industry experts, however, believe that Eli Lilly paid too much for ImClone at a price of $6.5 billion."

*Free downloadable research report on Eli Lilly & Co. is available by signing up now at http://www.rothmanresearch.com/article/lly/23568/Jun-09-2010.html

Eli Lilly is planning to continue its workforce reduction up to the end of 2011 so as to minimize the financial challenges it will face from generic competition in the mid-term. The generic drugs space has been booming in recent years with an increase of 5.9% in the use of generic drugs in 2009. Overall generic products totaled about $74 billion in sales last year. Whilst the generic drugs sphere is dominated by a few key players like Teva and Dr. Reddy's, some intrepid contenders are starting to build momentum. One such company is Impax Laboratories (NASDAQ: IPXL) which is forging its way through the generic drugs industry with a number of hot potential products in the pipeline. The company has successfully been able to take advantage of off-patent drugs and has several joint ventures with a number of large generics companies including Teva. Many pharma experts believe the company is set to grow in 2010 and 2011 as it has a good balance sheet and interesting pipeline.

*Complimentary downloadable research on Impax Laboratories Inc. is accessible upon registration at http://www.rothmanresearch.com/article/ipxl/23569/Jun-09-2010.html

Companies looking for additional media or advertising services can call Blue Chip IR at 1-917-267-8836

About Rothman Research Rothman Research brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities.

For More Information Contact: Jack Benassi info@rothmanresearch.com